Fed Circuit sides with Merck in antifungal treatment dispute

25-06-2019

Fed Circuit sides with Merck in antifungal treatment dispute

Atmosphere1 / Shutterstock.com

A US court has upheld a decision that eight claims of one of Mayne Pharma’s patents are unpatentable for obviousness over prior art after a validity challenge was brought by a subsidiary of Merck & Co.


Merck & Co, US Patent and Trademark Office, US Court of Appeals for the Federal Circuit, fungal infection, patent infringement, inter partes review

More on this story

Merck boosts oncology pipeline with $1bn deal
22-05-2019

LSIPR